Patents by Inventor Achim Guettner

Achim Guettner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20230321231
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 2, 2022
    Publication date: October 12, 2023
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • Methods of treating psoriasis using IL-17 antagonists
    Patent number: 11534490
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: December 27, 2022
    Assignee: NOVARTIS AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20210162044
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 3, 2021
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20210113688
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 22, 2021
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20200171147
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 4, 2020
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • Methods of treating psoriasis using IL-17 antibodies
    Patent number: 10583190
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: March 10, 2020
    Assignee: NOVARTIS AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20170304439
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: June 22, 2017
    Publication date: October 26, 2017
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • Methods of treating psoriasis using IL-17 antibody
    Patent number: 9717791
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: August 1, 2017
    Assignee: Novartis AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20130202610
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: October 7, 2011
    Publication date: August 8, 2013
    Applicant: Novartis AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassillis, Oliver Sander